How to Mitigate Risk for Biologics During Fill/Finish Manufacturing

As more biologics move through research and development, the demand for specialized aseptic fill/finish services has steadily climbed. Aseptic processing with the highest degree of sterility assurance, filling accuracy and quality is critical for high-value, small-batch therapies. Anything less impacts regulatory compliance, project timelines and—most importantly—patient safety.

This white paper explores the specialized equipment, expertise, and services needed for efficient biologics fill/finish manufacturing. Top takeaways include:

  • The benefits of single-use aseptic filling systems and gloveless robotic handling
  • How automation can reduce variability and speed up manufacturing
  • How to maintain yield and prevent impurities during scale-up
  • Qualities to look for in a biologics service provider

By: Dan Perrin, Director of Manufacturing, Winnipeg, MB, Canada

DOWNLOAD WHITE PAPER

All Hands on Deck for Fill/Finish of Vaccines and Therapeutics

“Emergent has a long, successful history of working with the US government to develop, manufacture, and deliver safe and...

READ MORE

Facility Spotlight: Drug Product Manufacturing in Maryland

Located just 10 minutes from Emergent headquarters, our 70,000 sq. ft. Rockville, MD (USA) facility provides drug product...

READ MORE

3 Things Manufacturers Need to Know About the New Annex 1 Revision

In August 2023, long-awaited drug manufacturing regulations took effect with the implementation of the European Commission’s...

READ MORE